Mechanistic Studies of Ligand-Regulated Nuclear Receptor RXR Activity

配体调节核受体 RXR 活性的机制研究

基本信息

  • 批准号:
    7502383
  • 负责人:
  • 金额:
    $ 22.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-17 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of our research is to unravel the molecular basis of the nuclear receptor actions using X-ray crystallography in conjunction with multidisciplinary molecular and biochemical approaches. The nuclear receptor retinoid X receptors (RXRs) are key ligand-activated transcriptional regulators involved in a wide range of human physiology, including development and metabolism. RXRs are well-established drug targets. However, the clinical use of RXR ligands is clearly tempered by side effects like toxicity, possibly associated with their low selectivity and affinity and also the cross-reactivity with other functions of RXRs. To understand the molecular basis of ligand-mediated signaling of RXRs in human physiology, we are planning to determine the crystal structures of a RXR multi-domain fragment bound to a DNA response fragment of their target genes. Following structure determination, we will perform mutational studies, biochemical analysis, and cell-based transcriptional assays to confirm functional significance of key structure elements. This study will reveal the molecular basis of the functional specificity of RXRs and its ligands at key regulatory steps: from ligand binding and to target gene recognition. The structural insights will provide a rational template for structure-based drug discovery of highly selective and efficient RXR ligands with reduced side effects for the therapeutic use in human disease. Moreover, the structure generated in this project will serve as a model to study the ligand-dependent regulation of other nuclear receptor family members. PUBLIC HEALTH RELEVANCE: This proposal addresses a critical need in the current nuclear receptor research by providing three-dimensional structures of the multi-domain retinoid X receptor bound to its target genes. The structural and functional studies will reveal detailed insights on how drug specificity and affinity can be further improved, thus providing a foundation for rational drug discovery for effective treatment of human disease like metabolic disease.
描述(由申请人提供):我们研究的目标是使用X射线晶体学结合多学科分子和生物化学方法来阐明核受体作用的分子基础。核受体类维生素A X受体(RXR)是参与广泛的人类生理学(包括发育和代谢)的关键配体激活的转录调节因子。RXR是公认的药物靶标。然而,RXR配体的临床使用明显受到副作用如毒性的影响,这可能与它们的低选择性和亲和力以及与RXR的其他功能的交叉反应性有关。为了了解RXR在人体生理学中配体介导的信号传导的分子基础,我们计划确定与其靶基因的DNA反应片段结合的RXR多结构域片段的晶体结构。结构确定后,我们将进行突变研究,生化分析和基于细胞的转录测定,以确认关键结构元件的功能意义。这项研究将揭示RXR及其配体在关键调控步骤的功能特异性的分子基础:从配体结合到靶基因识别。结构的见解将提供一个合理的模板,为基于结构的药物发现的高度选择性和有效的RXR配体与减少的副作用,用于人类疾病的治疗用途。此外,在这个项目中产生的结构将作为一个模型,研究其他核受体家族成员的配体依赖性调节。公共卫生相关性:这一提议通过提供与其靶基因结合的多结构域维甲酸X受体的三维结构来解决当前核受体研究中的关键需求。结构和功能研究将揭示如何进一步提高药物特异性和亲和力的详细见解,从而为合理的药物发现提供基础,以有效治疗人类疾病,如代谢疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yong Li其他文献

A chimeric vacuolar Na+/H+ antiporter gene evolved by DNA family shuf?ing confers increased salt tolerance in yeast
由 DNA 家族改组进化而来的嵌合液泡 Na /H 逆向转运蛋白基因可增强酵母的耐盐性
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yong Li;Hailing Gao;Jiang Wu;Wenzhu Guan
  • 通讯作者:
    Wenzhu Guan

Yong Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yong Li', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10745011
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
Optimizing Syngeneic Mouse Models to Target Mutant p53
优化同基因小鼠模型以靶向突变 p53
  • 批准号:
    10677353
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
Cancer Prevention-Interception Against MGUS Progression
癌症预防——阻止 MGUS 进展
  • 批准号:
    10745010
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI
使用人工智能针对非霍奇金淋巴瘤驱动者进行治疗
  • 批准号:
    10585717
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
Dietary Carcinogens for Colorectal Cancer
结直肠癌的膳食致癌物
  • 批准号:
    10160852
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:
TP53 Germline Mutations: Beyond LFS
TP53 种系突变:超越 LFS
  • 批准号:
    9912116
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:
Dietary Carcinogens for Colorectal Cancer
结直肠癌的膳食致癌物
  • 批准号:
    10401445
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:
Modulation of MicroRNAs with Xenobiotics to Target c-Myc
用异生素调节 MicroRNA 以靶向 c-Myc
  • 批准号:
    10018536
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:
Dietary Carcinogens for Colorectal Cancer
结直肠癌的膳食致癌物
  • 批准号:
    10040844
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
MYC 作为侵袭性非霍奇金淋巴瘤的生物标志物
  • 批准号:
    10019120
  • 财政年份:
    2019
  • 资助金额:
    $ 22.73万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了